AstraZeneca PLC (LON:AZN) rose on Monday as it completed the sale of rights to five medicines used to treat hypertension to private UK company Atnahs Pharma for US$350mln.
The initial payment may be followed by optional instalments of up to US$40mln based on sales, the FTSE 100-listed pharma giant said.
READ: AstraZeneca sells rights for constipation drug to RedHill Biopharma
In 2018, the five drugs - Inderal, Tenormin, Tenoretic, Zestril, Zestoretic - made combined annual sales of US$132mln.
Shares advanced 4% to 7,048p on Monday morning.